NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Patiromer for treating hyperkalaemia [ID877]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
 Vifor Pharma (patiromer) 	Allied Health Professionals
	All Wales Therapeutics and Toxicology
Patient/carer groups	Centre
Kidney Care UK	 Association of Renal Industries
Kidney Research UK	Board of Community Health Councils in
 Muslim Council of Great Britain 	Wales
 National Kidney Federation 	British National Formulary
 Pumping Marvellous Foundation 	Care Quality Commission
 South Asian Health Foundation 	Department of Health, Social Services
Specialised Healthcare Alliance	and Public Safety for Northern Ireland
	Healthcare Improvement Scotland
Professional groups	Medicines and Healthcare Products
 Association of Renal Technologists 	Regulatory Agency
British Geriatrics Society	National Association of Primary Care
British Renal Society	National Pharmacy Association
Renal Association	NHS Alliance
Royal College of General Practitioners	NHS Confederation
Royal College of Nursing	Scottish Medicines Consortium
Royal College of Pathologists	Welsh Health Specialised Services
Royal College of Physicians	Committee
Royal Pharmaceutical Society	Welsh Kidney Patients Association
Royal Society of Medicine	
UK Clinical Pharmacy Association	Comparator companies
UK Renal Pharmacy Group	• none
Others	Relevant research groups
Department of Health	Cochrane Kidney and Transplant
NHS England	MRC Clinical Trials Unit
NHS Cumbria CCG	National Institute for Health Research
NHS Mansfield & Ashfield CCG	
Welsh Government	Associated Public Health Groups
- Weight Government	Public Health England
	Public Health Wales

Appendix C

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Final matrix for technology appraisal of patiromer for treating hyperkalaemia [ID877] Issue date: May 2018

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.